Clinical Trials Browser

Phase 1/2 × OTHER_GOV × tislelizumab × Clear all

NCT05319639 2025-02-27

Phase I/II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab

Phase 1/2 Recruiting

Gastrointestinal

Stomach Neoplasms